ISPOR - HTA134 The Impact of Non-Comparative Data for Non-Orphan Drugs on HTA and Pricing Outcomes in Germany: Can an Added Benefit Ever be Proven?

HTA134 The Impact of Non-Comparative Data for Non-Orphan Drugs on HTA and Pricing Outcomes in Germany: Can an Added Benefit Ever be Proven?

Abstract

Authors

I. Owens-Smith K. Cullen

Full Text Cite This Article

Back to Volume 26, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now